Physician profile
Michael Charles Chappell
NPI 1497045645
$42,713.53
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.01 · 2020: $30.60 · 2021: $332 · 2022: $2,106 · 2023: $6,247 · 2024: $23K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $5,675 · Consulting Fee: $5,100 · Travel and Lodging: $4,633 · Food and Beverage: $2,671 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,100.00 |
| Honoraria | $5,675.00 |
| Consulting Fee | $5,100.00 |
| Travel and Lodging | $4,632.84 |
| Food and Beverage | $2,670.83 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33,795.47 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $8,701.90 | 2020-2023 | Tepezza |
| Genentech USA, INC. | $57.01 | 2019 | |
| Bausch & Lomb Americas INC. | $44.92 | 2024 | Xiidra, Vyzulta |
| Glaukos Corporation | $33.37 | 2020-2025 | |
| Abbvie INC. | $33.25 | 2025 | |
| Dompe US, INC. | $27.61 | 2025 | Oxervate |
| Sight Sciences, INC. | $20.00 | 2024 | Omni Surgical System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.